Challenges in Valve-in-Valve Therapy for Aortic Valves

Bapat, Vinayak; Attia, Rizwan; Aziz, Waqar; Radia, Rahee; Prione, Francesco

doi:10.1007/978-1-4939-3432-4_9

Cited by 1 publication

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The knowledge of the previously implanted surgical valve is essential for the feasibility and planning of TAVR-in-SAVR: the dedicated mobile application for VIV represents an important tool to know the characteristics of surgical aortic valves and for the procedural guidance. 94 Strategies to address SVD or non-SVD are represented by either redo-SAVR or TAVR-in-SAVR. 95,96 Currently, data indicating the best treatment choice are lacking.…”

Section: Savr As First Therapymentioning

confidence: 99%

See 1 more Smart Citation

Lifetime Management of Aortic Stenosis: Transcatheter Versus Surgical Treatment for Young and Low-Risk Patients

Russo

Sangiorgi

Pedicino

et al. 2022

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Transcatheter aortic valve replacement is now indicated across all risk categories of patients with symptomatic severe aortic stenosis and has been proposed as first line option for the majority of patients >74 years old. However, median age of patients enrolled in the transcatheter aortic valve replacement low-risk trials is 74 years and transcatheter aortic valve replacement has never been systematically investigated in young low risk patients. Although the long-term data in surgical aortic valve replacement in young patients (age <75) are well known, such data remain lacking in transcatheter aortic valve replacement. In the absence of clear guideline recommendations in patients with challenging anatomies (eg, hostile calcium, bicuspid), it is important to know the potential advantages and disadvantages of each treatment and to consider how they might integrate with each other in the lifetime management of such patients. In this review, we discuss current outstanding issues on the management of severe aortic stenosis from a lifetime management perspective, particularly in terms of initial intervention and future reinterventions.

show abstract

Section: Savr As First Therapymentioning

confidence: 99%

Section: Lifetime Management Strategy On Aortic Valve Reinterventionmentioning

confidence: 99%